Annegret Van der Aa

Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial

Séverine Vermeire, Stefan Schreiber, Robert Petryka et al. · The Lancet · 2016 · 439 citations

Pharmacy, Clinical Sciences, Pharmacotherapy +13

Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1)

René Westhovens, Peter C. Taylor, Rieke Alten et al. · Annals of the Rheumatic Diseases · 2016 · 234 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2)

Arthur Kavanaugh, Joel M. Kremer, L Ponce et al. · Annals of the Rheumatic Diseases · 2016 · 230 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial

Philip J. Mease, Laura C. Coates, Philip Helliwell et al. · The Lancet · 2018 · 204 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12

Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection

Florence Namour, Paul M. Diderichsen, Eugène Cox et al. · Clinical Pharmacokinetics · 2015 · 136 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +16